Silver Book Fact

“A treatment breakthrough that delayed the age of onset of Alzheimer’s disease by five years and began to show its effects in 2015 would decrease the total number of Americans age 65 and older with Alzheimer’s disease from 5.6 million to 4 million by 2020.  As a result, 1.6 million Americans who would be expected to have the condition in 2020 would be free of the condition.  In addition, five years later, in 2025, 2.7 million Americans–42 percent of the 6.5 million people who would be expected to have Alzheimer’s in that year–would be disease free.  The biggest effect would be in 2050 when 5.8 million people–43 percent of the 13.5 million Americans who would be expected to have Alzheimer’s without the breakthrough–would not have the condition.”

Alzheimer's Association. Changing the Trajectory of Alzheimer’s Disease: How a treatment by 2025 saves lives and dollars. Washington, D.C.: Alzheimer’s Association; 2010. http://www.alz.org/documents_custom/trajectory.pdf

Reference

Title
Changing the Trajectory of Alzheimer’s Disease: How a treatment by 2025 saves lives and dollars
Publisher
Alzheimer’s Association
Publication Date
2010
Authors
Alzheimer's Association
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • “A treatment breakthrough that delayed the age of onset of Alzheimer’s disease by five years and began to show its effects in 2015 would decrease the total number of Americans…  
  • Based on rates of admission in 1998, delaying admission of Alzheimer’s patients to nursing homes by 1 month could save as much as $1.12 billion a year.  
  • Recent studies suggest that a low-fat diet which is rich in fruits and vegetables may support brain health. Other studies suggest that remaining socially active and intellectually engaged may also…  
  • An Alzheimer’s disease treatment breakthrough that slowed its progression and began to show its effects in 2015, would reduce the Medicare costs for people with the disease by $20 billion…  
  • Current research supported by the National Institute of Neurological Disease Orders and Stroke (NINDS) at NIH is using animal models to study progression of the disease and develop new drugs…